[Biolojic in Business Wire] Teva and Biolojic Design announce exclusive license agreement for the development of a therapeutic antibody for Atopic Dermatitis and Asthma
TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. (“Biolojic”), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma. Read...
Read More